Collate Biotech Startup Secures $30M Seed Fund for Automation Revolution
Surbhi Sarna, a prominent figure in the entrepreneurial and life sciences realms, has launched her latest endeavor, Collate. In a recent announcement on LinkedIn, Sarna, the CEO, and founder, revealed the successful completion of Collate’s $30 million seed funding round.
A Personal Journey Fueling Innovation
Sarna’s journey into the world of startups and life sciences was sparked by a personal health scare during her teenage years. Battling ovarian cysts, she founded nVision Medical, developing the first FDA-cleared device for early ovarian cancer detection. This venture led to nVision’s acquisition by Boston Scientific for $275 million in 2018, showcasing Sarna’s entrepreneurial prowess.
Revolutionizing Life Sciences Through AI Automation
Drawing from her experiences at Y Combinator (YC), where she served as a partner, Sarna recognized an untapped opportunity in the intersection of documentation and AI. This realization prompted her departure from YC to establish Collate, aiming to transform the life sciences industry by automating labor-intensive documentation processes through AI.
Empowering Innovation in Healthcare
Collate’s AI platform promises to streamline paperwork for companies involved in diagnostics, medical devices, and drug development, facilitating faster research and development cycles, optimizing clinical trials, improving quality management, and reducing time-to-market for new healthcare solutions.
With a $30 million seed round led by Redpoint and participation from First Round, Conviction Partners, and YC, Collate’s valuation surpasses $100 million. Satish Dharmaraj of Redpoint highlights the platform’s potential for significant long-term impact, foreseeing a future of high-value, enduring relationships with clients.
Sarna’s co-founders, Nate Smith and Jigish Patel, bring additional expertise to Collate, enhancing the company’s innovative approach to AI integration in life sciences documentation. Smith’s seamless partnership with Sarna underscores the natural synergy driving Collate’s success in the healthcare landscape.
In her quest to build a vibrant company culture and assemble a talented team, Sarna emphasizes the importance of swift, precise decision-making in advancing Collate’s mission to empower healthcare companies to focus on enhancing human health.
Through Collate’s groundbreaking AI solutions, the healthcare industry is poised to embrace a new era of efficiency and innovation, unlocking possibilities for transformative advancements in human well-being.